KRAS and non-small cell lung carcinoma: The approval for sotorasib was based on CodeBreaK 100, a multicenter, single-arm, open-label clinical trial (NCT03600883) that included patients with locally advanced or metastatic NSCLC with KRAS G12C mutations.